mucos
vaccin
effect
strategi
gener
antigenspecif
immun
respons
mucos
infect
footandmouth
diseas
viru
fmdv
studi
lactobacillu
plantarum
strain
use
oral
deliveri
vehicl
contain
recombin
plasmid
initi
mucos
system
immun
respons
guinea
pig
guinea
pig
oral
vaccin
three
dose
milk
anim
immun
develop
high
level
antigenspecif
serum
igg
iga
igm
mucos
secretori
iga
siga
neutral
antibodi
reveal
stronger
cellmedi
immun
respons
enhanc
protect
fmdv
challeng
compar
control
group
recombin
effect
improv
immunoprotect
fmdv
guinea
pig
footandmouth
diseas
fmd
highli
contagi
diseas
livestock
outbreak
fmd
caus
sever
financi
loss
often
lead
quarantin
export
limit
affect
countri
well
cull
herd
day
incub
period
affect
anim
develop
acut
onset
high
fever
follow
vesicl
format
mouth
pharynx
feet
affect
anim
suffer
pain
refus
feed
saliv
extens
causal
pathogen
fmdv
belong
genu
aphthoviru
famili
picornavirida
includ
seven
serotyp
c
asia
virion
high
potenti
genet
antigen
variat
crossprotect
antibodi
form
infect
vaccin
serotyp
subtyp
fmdv
confound
effort
vaccin
program
prevent
diseas
viral
genom
posit
chemic
compet
e
coli
takara
transform
appli
protocol
provid
manufactur
lactobacilli
electrotransform
accord
protocol
aukrust
et
al
follow
modif
instead
glycin
use
prepar
electrocompet
lactobacilli
cell
wash
three
time
wash
buffer
naphosph
mgcl
ph
resuspend
ecoli
clone
strain
takara
l
plantarum
ccug
host
strain
plasmidfre
l
plantarum
host
strain
plasmidfre
electropor
buffer
sucros
mgcl
ph
store
stationari
phase
h
cultur
recipi
lactobacillu
strain
inocul
inoculum
vv
ml
mr
broth
contain
glycin
without
antibiot
without
shake
cell
harvest
od
h
put
ice
minut
centrifug
rmin
minut
wash
two
time
equal
cultur
volum
icecold
wash
buffer
cell
resuspend
ml
icecold
sucrosemagnesium
chlorid
electropor
buffer
smeb
recombin
plasmid
dna
mix
icecold
compet
cell
smeb
mixtur
place
ice
minut
transfer
prechil
cuvett
interelectrod
distanc
cm
biorad
singl
electr
puls
vcm
deliv
via
gene
pluster
tm
biorad
suspens
immedi
put
ice
minut
recoveri
medium
ad
mr
broth
without
antibiot
contain
glycin
bacteria
incub
h
without
agit
last
recombin
strain
select
mr
agar
medium
contain
erythromycin
analysi
express
recombin
strain
grown
h
mr
broth
contain
erythromycin
without
shake
overnight
cultur
inocul
inoculum
vv
mr
medium
induc
ad
sppip
ngml
od
h
cell
harvest
od
h
induct
centrifug
rmin
bacteri
cell
wash
three
time
steril
phosphatebuff
salin
pb
ph
resuspend
lysi
buffer
trishcl
mutanolysinml
lysozymeml
mm
glucos
roch
complet
proteas
inhibitor
bacteria
centrifug
rmin
minut
pellet
resuspend
analysi
via
sodium
dodecyl
sulphatepolyacrylamid
gel
electrophoresi
sdspage
protein
extract
electrotransf
onto
nitrocellulos
membran
western
blot
analysi
use
swine
antifmdv
antibodi
prepar
previous
laboratori
dilut
horseradishperoxidas
hrp
conjug
goat
antiswin
igg
antibodi
abbkin
inc
usa
dilut
visual
chemiluminesc
substrat
reagent
accord
manufactur
instruct
cell
grown
mr
medium
contain
erythromycin
induc
od
harvest
od
wash
pb
resuspend
milk
five
group
n
clean
guinea
pig
oral
dose
lactobacillu
strain
ml
syringevaccin
everi
day
cfu
coloni
form
unit
milk
three
target
sourc
sens
primer
gac
atg
tcc
tcc
tgc
atc
gene
work
antisens
primer
cac
aaa
tgt
aca
ggg
atg
ggt
gene
consecut
day
ie
anim
vaccin
day
use
milk
control
group
tabl
day
preimmun
anticoagul
whole
blood
sampl
blood
sampl
serum
test
collect
whole
blood
heart
mg
fecal
sampl
obtain
everi
day
steril
pb
ph
contain
moll
edtana
incub
h
saliva
sampl
also
collect
everi
day
mouth
guinea
pig
use
steril
rayon
ball
soak
pb
mm
proteas
inhibitor
clear
extract
sampl
store
subsequ
analysi
detect
antibodi
use
enzymelink
immunosorb
assay
elisa
specif
igg
serum
test
use
indirect
elisa
eiaria
micropl
costar
corn
inc
coat
h
fmdva
antigen
three
time
wash
pb
tween
pbst
well
block
h
pbst
contain
skim
milk
prevent
nonspecif
bind
wash
three
time
serum
dilut
react
coat
well
h
plate
wash
three
time
hrpconjug
goat
antiguinea
pig
igg
antibodi
dilut
use
detect
bound
antibodi
plate
incub
addit
minut
anoth
three
wash
colour
develop
carri
use
ophenylenediamin
opd
substrat
optic
absorb
measur
nm
within
minut
ad
stop
buffer
elisa
test
studi
cut
valu
defin
mean
od
plu
deviat
sd
sampl
guinea
pig
use
studi
immun
captur
elisa
test
use
detect
iga
igm
serum
well
siga
saliva
fece
accord
protocol
satya
et
al
micropl
coat
h
room
temperatur
rt
rabbit
antiserum
fmdv
dilut
wash
three
time
pbst
fmdva
antigen
dilut
ad
well
incub
h
wash
step
test
sampl
ad
well
serum
dilut
saliva
dilut
fece
dilut
incub
h
plate
wash
three
time
hrpconjug
goat
antiguinea
pig
igaigm
antibodi
use
detect
bound
antibodi
dilut
incub
addit
minut
three
time
wash
colour
develop
carri
use
opd
substrat
optic
absorb
measur
nm
within
minut
ad
stop
buffer
serum
sampl
obtain
guinea
pig
day
analyz
neutral
antibodi
titer
use
neutral
assay
monolay
cell
sera
sampl
tabl
immun
group
number
immun
dose
cfuml
vaccin
ad
well
doubl
ratio
dilut
method
dmem
gibco
contain
fb
plate
ad
sera
sampl
serum
inactiv
incub
minut
sampl
obtain
guinea
pig
immun
oral
empti
vector
milk
use
control
fmdv
adjust
tcid
dmem
contain
fb
ad
cell
plate
contain
serial
dilut
serum
antibodi
viru
mixtur
mix
incub
h
bhk
cell
cellsml
ad
antibodyviru
mixtur
incub
co
day
incub
cpe
measur
microscopi
sera
dilut
count
neg
sera
control
blank
control
cpe
supernat
medium
discard
stationari
liquid
formaldehyd
ad
well
incub
minut
stain
formaldehyd
contain
methylen
blue
solut
anoth
min
readmuench
method
use
calcul
neutral
antibodi
titer
neutral
antibodi
titer
calcul
log
reciproc
final
serum
dilut
neutral
tcid
viru
well
five
guinea
pig
immun
group
control
dissect
asept
condit
singlelymphocyt
suspens
prepar
spleen
day
cell
label
carboxyfluorescein
succinimidyl
ester
cfse
describ
previous
cfselabel
cell
wash
three
time
pb
contain
fb
resuspend
roswel
park
memori
institut
medium
plu
fb
mm
hepe
mm
ml
cell
suspens
ad
well
plate
cellsml
cell
stimul
concanavalin
con
posit
control
inactiv
fmdv
antigen
specif
antigen
stimul
cultur
medium
neg
control
respect
group
contain
three
parallel
well
incub
co
h
incub
lymphocyt
collect
concentr
centrifug
rmin
minut
wash
three
time
pb
final
resuspend
pb
data
cell
prolifer
acquir
facsaria
flow
cytomet
bd
usa
blood
sampl
day
obtain
anticoagul
agent
edta
stain
r
phycoerythrin
rpe
conjug
mous
antiguinea
pig
antibodi
fluorescein
isothiocyan
fitc
conjug
mous
antiguinea
pig
antibodi
minut
room
temperatur
rt
use
blood
sampl
rpe
fitc
conjug
mous
antibodi
neg
control
blood
blank
control
subsequ
fac
lyse
solut
bd
fac
tm
ad
sampl
lyse
blood
cell
minut
rt
cell
pellet
resuspend
pb
three
wash
detect
facsaria
flow
cytomet
forti
day
first
immun
anesthet
guinea
pig
challeng
subcutan
intraderm
left
rear
leg
ml
fmdv
serotypea
day
challeng
protect
fmdv
examin
clinic
sign
follow
guinea
pig
show
fmdcompat
lesion
origin
inject
site
judg
protect
show
fmd
clinic
sign
three
feet
judg
unprotect
data
handl
analysi
graphic
represent
perform
use
graphpad
prism
softwar
san
diego
ca
data
analyz
express
mean
error
valu
onetail
test
use
comparison
differ
consid
statist
signific
p
valu
less
express
l
plantarum
mucos
immun
guinea
pig
studi
measur
iga
respons
serum
oral
immun
day
substanti
differ
mucos
iga
level
experiment
control
group
milk
fig
c
p
seven
day
follow
first
immun
day
iga
reach
high
level
experiment
group
p
obviou
increas
antibodi
control
group
receiv
milk
p
similar
result
siga
antibodi
obtain
fecal
salivari
sampl
immun
guinea
pig
fig
b
second
immun
day
concentr
serum
iga
experiment
group
appear
lower
origin
level
first
immun
p
compar
mucos
iga
level
signific
antibodi
observ
control
group
p
concentr
igm
immun
guinea
pig
also
determin
fig
e
p
third
immun
igm
antibodi
rose
highest
level
group
p
although
increas
neg
milk
control
p
modest
signal
immun
anim
fmdvspecif
system
immun
respons
guinea
pig
studi
measur
igg
respons
serum
result
show
fig
substanti
differ
igg
level
experiment
control
group
day
p
seven
day
follow
first
immun
day
igg
obtain
high
level
experiment
group
p
concentr
igg
experiment
group
rose
second
immun
day
reach
highest
level
third
immun
day
p
signific
elicit
igg
antibodi
observ
milk
neg
control
group
p
slight
increas
igg
note
group
taken
togeth
result
indic
oral
administ
abl
elicit
fmdvspecif
system
mucos
antibodi
respons
moreov
mucos
immun
respons
occur
earlier
system
respons
also
declin
rapidli
investig
cellular
immun
respons
oral
immun
lactobacillu
strain
incorpor
recombin
plasmid
cell
assay
flow
cytometri
blood
sampl
obtain
third
vaccin
demonstr
fig
cell
cell
group
rose
higher
level
control
group
singlecel
suspens
lymphocyt
prepar
immun
guinea
pig
day
h
cultiv
suspens
stimul
concanavalin
posit
controlresult
evid
prolifer
medium
neg
controlwith
anticip
dormanc
evid
group
produc
significantli
high
level
cell
prolifer
stimul
activ
fmdv
specif
antigen
fig
obviou
prolifer
occur
control
group
result
indic
lactobacillu
strain
express
protein
could
induc
antigenspecif
cell
respons
antivir
neutral
serum
antibodi
titer
immun
guinea
pig
assess
fig
f
serum
sampl
obtain
vaccin
anim
day
first
immun
antibodi
respons
guinea
pig
oral
immun
exhibit
higher
fmdvneutral
activ
control
group
respons
shown
cytopath
effect
cpe
inhibit
indic
could
induc
neutral
antibodi
fmdv
guinea
pig
challeng
gpid
guinea
pig
infecti
dose
homotyp
viru
day
first
immun
protect
effect
oral
vaccin
evalu
ten
day
continu
observ
postchalleng
percentag
anim
group
exhibit
clinic
sign
fever
swollen
sole
secondari
vesicl
follow
group
group
group
milk
group
shown
tabl
vaccin
provid
least
partial
protect
fmdv
although
vaccin
use
control
even
erad
fmd
part
world
sinc
earli
diseas
still
infect
million
anim
year
remain
main
sanitari
barrier
commerc
anim
anim
product
vaccin
main
prophylact
method
prevent
fmdv
infect
mani
type
vaccin
designedalmost
entir
parenter
administeredinclud
inactiv
antigen
vaccin
live
attenu
vaccin
dna
vaccin
empti
capsid
vaccin
synthet
peptid
vaccin
inactiv
viru
vaccin
elicit
high
level
neutral
antibodi
offer
efficaci
protect
homolog
serotyp
howev
vaccin
shortcom
includ
revers
virul
insuffici
stabil
creation
viral
carrier
state
vaccin
prevent
viru
enter
bodi
via
mucosa
fmdv
infect
gener
occur
mucos
surfac
make
mucos
immun
specif
vaccin
antigen
attract
option
protect
infect
intranas
deliveri
cation
plga
nanomicroparticl
load
variou
fmdv
dna
vaccin
formul
encod
molecular
adjuv
enhanc
protect
immun
infect
aerosol
fmdv
anoth
studi
also
suggest
intranas
deliveri
chiplgadna
nanoparticl
fmdv
antigen
result
high
level
mucos
system
cellmedi
immun
could
reduc
diseas
sever
viru
excret
well
delay
clinic
symptom
stand
statist
signific
differ
rel
milk
control
repres
statist
signific
differ
rel
control
p
abbrevi
ig
immunoglobulin
sd
standard
deviat
mani
avail
approach
stimul
effici
mucos
respons
deliv
protein
peptid
antigen
associ
appropri
adjuv
eg
liposom
iscom
stimul
cellular
humor
immun
respons
particul
form
link
latex
microspher
use
recombin
live
vector
eg
attenu
viru
bacteria
use
lactobacilli
carrier
deliv
exogen
vaccin
antigen
cytosol
effici
appear
one
success
strategi
first
genom
annot
lactobacillu
strain
found
possess
function
homolog
signal
peptid
sequenc
isol
grass
silag
possess
unusu
properti
natur
plasmid
free
among
l
plantarum
strain
two
l
plantarum
colon
gitract
recogn
emerg
candid
express
recombin
protein
well
genet
metabol
cell
engin
relev
medic
industri
biotechnolog
oral
administr
lactobacilli
recombin
protein
situ
mani
advantag
safe
conveni
less
stress
among
anim
reduct
advers
reaction
besid
lactobacilli
live
vector
persist
longer
gitract
intrins
probiot
properti
gene
use
studi
gene
hot
area
research
molecular
biolog
fmdv
year
protein
expos
surfac
viral
particl
main
antigen
neutral
antibodi
respons
play
import
part
form
viru
particl
past
decad
partial
complet
code
sequenc
use
develop
engin
vaccin
accommod
largescal
product
recombin
protein
effici
produc
express
variou
system
e
coli
transgen
plant
yeast
baculoviru
mammalian
cell
sequenc
gene
optim
base
pool
codon
use
l
plantarum
reduc
gc
content
without
chang
gene
express
improv
translat
perform
studi
psip
express
system
use
express
protein
studi
current
underway
employ
lactic
acid
bacteria
vector
produc
vaccin
mani
viral
protein
hemagglutinin
ha
gene
avian
influenza
viru
antirotaviru
protein
llama
vhh
antibodi
fragment
bioactiv
porcin
interferonalpha
two
l
plantarum
strain
chosen
studi
carri
psip
plasmid
compar
result
western
blot
two
strain
found
molecular
weight
target
protein
express
littl
bigger
protein
express
account
posttransl
modif
phosphoryl
acetyl
milk
use
resuspend
strain
studi
order
improv
tast
anim
make
oral
administr
safe
easi
addit
choos
induct
temperatur
imit
intern
temperatur
guinea
pig
suitabl
temperatur
rang
l
plantarum
respiratori
tract
oral
administr
recombin
l
plantarum
induc
siga
antibodi
consid
major
effector
adapt
immun
defens
respiratori
mucosa
iga
antibodi
emerg
antigen
invad
mucosa
earlier
igg
antibodi
indic
iga
function
earli
stage
viral
infect
current
studi
demonstr
high
level
fmdvspecif
iga
produc
serum
saliva
fece
support
import
iga
antibodi
respons
prevent
entri
replic
fmdv
howev
full
mechan
underli
decreas
respiratori
tract
infect
symptom
still
uncertain
product
igg
antibodi
occur
later
iga
level
becam
higher
last
longer
iga
taken
togeth
result
suggest
mucos
respons
induc
recombin
l
plantarum
interact
system
respons
result
first
report
immun
effect
guinea
pig
use
psip
system
two
l
plantarum
host
strain
via
oral
immun
data
obtain
clearli
demonstr
oral
administr
protein
express
could
induc
mucos
respons
system
respons
provid
good
protect
fmdv
challeng
mucos
administr
vaccin
strain
result
detect
fmdvspecif
igg
iga
respons
howev
frequent
mutat
gene
region
field
isol
protein
base
immun
produc
effect
stabl
immun
respons
long
period
time
research
seek
altern
gene
carri
effect
immunodomin
epitop
less
mutat
exampl
fmdv
believ
carri
immunodomin
epitop
public
reveal
protein
show
import
immunolog
characterist
develop
fmdv
vaccin
studi
still
preliminari
stage
studi
laboratori
explor
immun
effect
fmdv
gene
segment
combin
immunolog
adjuv
instanc
ifn
express
lab
via
mucos
rout
differ
anim
model
especi
larg
anim
past
two
decad
studi
mucos
administ
recombin
lab
rlab
use
anim
model
success
demonstr
major
health
benefit
field
recent
move
era
human
clinic
trial
enough
prove
potenti
rlab
therapeut
tool
safe
effici
use
despit
good
applic
prospect
rlab
therapeut
deliveri
vehicl
still
mani
question
remain
unansw
dose
therapeut
protein
deliv
situ
rlab
oral
administr
effect
immun
rout
intranas
rout
oral
rout
best
period
life
neonat
adult
studi
earli
stage
fmd
oral
vaccin
need
test
enhanc
immun
effect
studi
carri
larger
anim
suscept
fmdv
swine
bovin
studi
requir
consid
immun
effect
comparison
intranas
immun
oral
immun
coexpress
larger
fragment
cytokin
mani
expert
anticip
next
decad
applic
rlab
therapeut
tool
develop
optim
lab
deliveri
true
realist
option
human
anim
medicin
conclus
oral
live
carrier
vaccin
promis
strategi
present
fmdv
antigen
provid
effect
inexpens
stabl
altern
current
approach
immun
fmdv
